Efficacy of a probiotic supplement in patients with atopic dermatitis: a randomized, double-blind, placebo-controlled clinical trial.

What Was Tested

The paper reports a study of Copper (Supplement), published as a randomized controlled trial.

Atopic dermatitis (AD) is a multifactorial long-standing inflammatory skin disease with a high incidence worldwide in both adults and children.

According to the recognized correlation between skin and intestine-the so-called "gut-skin axis"-gut unbalances can affect skin by inducing systemic inflammation and triggering dermatological diseases such as AD.

Who Took Part

PubMed indexes the participants as adults, both men and women.

The latter was chosen according to the patients' production of post-biotic metabolites and B-group vitamins, anti-inflammatory and anti-oxidant capacity and anti-microbial activity.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Copper (Supplement) and who got the comparison, which limits bias.

As a double-blind Copper (Supplement) study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Copper (Supplement) could be set against what happens without it.

Inflammatory cytokine levels from skin tape stripping, sampled close to AD lesions at T0d and T56d, were also measured.

What Was Measured

According to the recognized correlation between skin and intestine-the so-called "gut-skin axis"-gut unbalances can affect skin by inducing systemic inflammation and triggering dermatological diseases such as AD.

Topics PubMed links to this paper include Chemokine CCL17, Cytokines, Dermatitis, Atopic, Edema, Erythema, Probiotics and Pruritus.

Author keywords: SCORAD, adult subjects, atopic dermatitis and randomized controlled trial.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement).

Its findings take up roughly 2 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (European journal of dermatology : EJD), a journal based in France.

More context: the Copper (Supplement) compound page, all human trials.